Newsroom 2022
Everything BrainStorm published in 2022.
Latest from BrainStorm
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn®
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to discuss the contents of a refusal to file letter previously issued re
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the company has submitted a Type A Meeting Request to the U.S. Food and Drug Administration (FDA) to discuss the contents of a refusal to file le
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Biologics License Applicatio
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2022, and provide a corporat
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of a poster with new analyses from NurOwn's placebo-controlled Phase 3 amyotrophic lateral sclerosis (ALS) trial that account for limitations i
BrainStorm Cell Therapeutics Presents NurOwn Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that a scientific abstract titled 'NurOwn (MSC-NTF) Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers' will be presented at th
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the presentation of new biomarker analyses supporting the therapeutic benefit of NurOwn in amyotrophic lateral sclerosis (ALS) at the ongoing 5th Ann
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer reviewed publication of data from the Phase 2 trial of NurOwn in progressive multiple sclerosis (MS) in Multiple Sclerosis Journal. The publication, en
BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update. The company also announced its decision to submit a Bio
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update,
BrainStorm Announces Presentations at June 2022 Scientific Conferences
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at forthcoming ALS and MS scientific conferences in June 2022. Insights into the ALS Phase 3 primary endpoint leveraging ENCALS model patient prog
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the first quarter ended March 31, 2022 and provided a corporate update.
BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced two senior management appointments. Netta Blondheim Shraga, PhD has been appointed as VP, Research & Development, and Antal Pearl-Lendner, Adv. has been appointed to
BrainStorm Announces Presentation of NurOwn Exosome Preclinical Data at ISCT 2022 San Francisco Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived f
BrainStorm Announces Upcoming Scientific Conference Presentations
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022. New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (M
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2022, and provide a corporate upd
Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT
Brainstorm Cell Therapeutics (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative disease, announced today that the company President and Chief Medical Officer, Ralph Kern, MD MHSc has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group
BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate Update
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the financial results for the fiscal year ended December 31, 2021 and provided a corporate update.
BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2021, and provide a
BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA (Muscular Dystrophy Association) Clinical & Scientific Co
Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Brazilian Patent Office has granted the patent application titled: "A method of generating cells which secrete Brain Derived Neurotrophic Fac
BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research Summit
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D., MHSc, President and Chief Medical Officer of BrainStorm Cell Therapeutics, will provide a corporate and clinical overview at th
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, M.D. MHSc, President and Chief Medical Officer of Brainstorm Cell Therapeutics, will provide a corporate and clinical overview at Bio
No press releases match that search. Try a shorter phrase, or clear the field to see the full list.
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.